BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 14980127)

  • 21. Interferon-alpha therapy within the first year after acute hepatitis C infection in hemodialysis patients: efficacy and tolerance.
    Rocha CM; Perez RM; Narciso JL; Ferreira AP; Lemos LB; Medina-Pestana JO; Silva AE; Ferraz ML
    Eur J Gastroenterol Hepatol; 2007 Feb; 19(2):119-23. PubMed ID: 17272996
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term follow-up after successful interferon therapy of acute hepatitis C.
    Wiegand J; Jäckel E; Cornberg M; Hinrichsen H; Dietrich M; Kroeger J; Fritsch WP; Kubitschke A; Aslan N; Tillmann HL; Manns MP; Wedemeyer H
    Hepatology; 2004 Jul; 40(1):98-107. PubMed ID: 15239091
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bismacrocyclic inhibitors of hepatitis C NS3/4a protease.
    McCauley JA; Rudd MT; Nguyen KT; McIntyre CJ; Romano JJ; Bush KJ; Varga SL; Ross CW; Carroll SS; DiMuzio J; Stahlhut MW; Olsen DB; Lyle TA; Vacca JP; Liverton NJ
    Angew Chem Int Ed Engl; 2008; 47(47):9104-7. PubMed ID: 18925594
    [No Abstract]   [Full Text] [Related]  

  • 24. [Latest advances in anti-virus therapy for hepatitis B: A report from the 55th Annual Meeting of the American Association for the Study of Liver Diseases].
    Zhang DF
    Zhonghua Gan Zang Bing Za Zhi; 2004 Dec; 12(12):708-10. PubMed ID: 15619333
    [No Abstract]   [Full Text] [Related]  

  • 25. Oligonucleotide-based therapeutic options against hepatitis C virus infection.
    Trepanier JB; Tanner JE; Alfieri C
    Antivir Ther; 2006; 11(3):273-87. PubMed ID: 16759043
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New drug targets for HIV and hepatitis C virus coinfection.
    Tedaldi EM
    Clin Infect Dis; 2005 Jul; 41 Suppl 1():S101-4. PubMed ID: 16265606
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interfering with interferon: re-igniting the debate on calcineurin inhibitor choice and antiviral therapy for hepatitis C virus recurrence.
    Watashi K; Metselaar HJ; van der Laan LJ
    Liver Transpl; 2008 Mar; 14(3):265-7. PubMed ID: 18306373
    [No Abstract]   [Full Text] [Related]  

  • 28. American Association for the Study of Liver Diseases (AASLD)--56th Annual Meeting.
    Phend C
    IDrugs; 2006 Feb; 9(2):96-100. PubMed ID: 16523396
    [No Abstract]   [Full Text] [Related]  

  • 29. A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy.
    Balan V; Nelson DR; Sulkowski MS; Everson GT; Lambiase LR; Wiesner RH; Dickson RC; Post AB; Redfield RR; Davis GL; Neumann AU; Osborn BL; Freimuth WW; Subramanian GM
    Antivir Ther; 2006; 11(1):35-45. PubMed ID: 16518958
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ribavirin/interferon-alpha sequential treatment of recurrent hepatitis C after liver transplantation.
    Giostra E; Kullak-Ublick GA; Keller W; Fried R; Vanlemmens C; Kraehenbuhl S; Locher S; Egger HP; Clavien PA; Hadengue A; Mentha G; Morel P; Negro F
    Transpl Int; 2004 May; 17(4):169-76. PubMed ID: 15060764
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient.
    Cubero M; Esteban JI; Otero T; Sauleda S; Bes M; Esteban R; Guardia J; Quer J
    Virology; 2008 Jan; 370(2):237-45. PubMed ID: 18006035
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Spectrum of pulmonary toxicity associated with the use of interferon therapy for hepatitis C: case report and review of the literature.
    Midturi J; Sierra-Hoffman M; Hurley D; Winn R; Beissner R; Carpenter J
    Clin Infect Dis; 2004 Dec; 39(11):1724-9. PubMed ID: 15578378
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatitis C: staying the course.
    Garber K
    Nat Biotechnol; 2007 Dec; 25(12):1379-81. PubMed ID: 18066031
    [No Abstract]   [Full Text] [Related]  

  • 34. Hepatitis C--clinical profile.
    Bhandari B; Pal A
    J Indian Med Assoc; 2007 Aug; 105(8):453-4, 456, 465. PubMed ID: 18236909
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An efficient, asymmetric solid-phase synthesis of benzothiadiazine-substituted tetramic acids: potent inhibitors of the hepatitis C virus RNA-dependent RNA polymerase.
    Evans KA; Chai D; Graybill TL; Burton G; Sarisky RT; Lin-Goerke J; Johnston VK; Rivero RA
    Bioorg Med Chem Lett; 2006 Apr; 16(8):2205-8. PubMed ID: 16455253
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection.
    ; McCaughan GW; Omata M; Amarapurkar D; Bowden S; Chow WC; Chutaputti A; Dore G; Gane E; Guan R; Hamid SS; Hardikar W; Hui CK; Jafri W; Jia JD; Lai MY; Wei L; Leung N; Piratvisuth T; Sarin S; Sollano J; Tateishi R
    J Gastroenterol Hepatol; 2007 May; 22(5):615-33. PubMed ID: 17444847
    [No Abstract]   [Full Text] [Related]  

  • 37. Phase I clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to respond to interferon-based therapy.
    Yutani S; Yamada A; Yoshida K; Takao Y; Tamura M; Komatsu N; Ide T; Tanaka M; Sata M; Itoh K
    Vaccine; 2007 Oct; 25(42):7429-35. PubMed ID: 17845828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early prediction of hepatitis C virus (HCV) infection relapse in nonresponders to primary interferon therapy by means of HCV RNA whole-blood analysis.
    Watkins-Riedel T; Ferenci P; Steindl-Munda P; Gschwantler M; Mueller C; Woegerbauer M
    Clin Infect Dis; 2004 Dec; 39(12):1754-60. PubMed ID: 15578395
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
    Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Twenty-four hour kinetics of hepatitis C virus and antiviral effect of alpha-interferon.
    Boulestin A; Kamar N; Sandres-Sauné K; Legrand-Abravanel F; Alric L; Vinel JP; Rostaing L; Izopet J
    J Med Virol; 2006 Mar; 78(3):365-71. PubMed ID: 16419107
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.